A phase II trial of neoadjuvant erlotinib in patients with muscle‐invasive bladder cancer undergoing radical cystectomy: clinical and pathological results

Study Type – Therapy (cohort)
Level of Evidence 2b

[1]  J. Panetta,et al.  Pharmacokinetics of Erlotinib for the Treatment of High‐Grade Glioma in a Pediatric Patient with Cystic Fibrosis: Case Report and Review of the Literature , 2009, Pharmacotherapy.

[2]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[3]  K. Baggerly,et al.  Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. , 2008, The Journal of urology.

[4]  P. Schellhammer,et al.  Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. , 2007, The Journal of urology.

[5]  J. Brahmer,et al.  “Who Should Receive Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer and When?” , 2007, Current treatment options in oncology.

[6]  G. de Rosa,et al.  Expression of apoptosis-related markers in malignant epithelial tumours of the lacrimal gland and their relation to clinical outcome , 2007, British Journal of Ophthalmology.

[7]  Yair Lotan,et al.  Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. , 2007, European urology.

[8]  G. Clark,et al.  Effects of Smoking on the Pharmacokinetics of Erlotinib , 2006, Clinical Cancer Research.

[9]  Michelle L. Reyzer,et al.  Short course of EGF receptor tyrosine kinase inhibitor erlotinib (OSI-774) reduces tumor cell proliferation and active MAP kinase in situ in untreated operable breast cancers: A strategy for patient selection into phase II trials with signaling inhibitors , 2005 .

[10]  S. Fosså,et al.  Expression of the epidermal growth factor receptor family in normal and malignant urothelium , 2005, BJU international.

[11]  N. Normanno,et al.  The ErbB receptors and their ligands in cancer: an overview. , 2005, Current drug targets.

[12]  A. Halpern,et al.  HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. , 2005, The oncologist.

[13]  D. Polsky,et al.  Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patients , 2004, International journal of cancer.

[14]  G. Hall,et al.  Systemic chemotherapy for patients with bladder cancer--current controversies and future directions. , 2004, Cancer treatment reviews.

[15]  J. Lunec,et al.  Gefitinib (‘Iressa’, ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2 , 2004, British Journal of Cancer.

[16]  R. Goldberg,et al.  New targeted therapies in gastrointestinal cancers , 2003, Current treatment options in oncology.

[17]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[18]  C. Dinney,et al.  Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. , 2003, Critical reviews in oncology/hematology.

[19]  Ruth Katz,et al.  Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. , 2002, Cancer research.

[20]  J. Mellon,et al.  Epidermal growth factor receptor and bladder cancer , 2002, Postgraduate medical journal.

[21]  Clinic Pio Xi,et al.  Neo-adjuvant and adjuvant chemotherapy of bladder cancer: Is there a role? , 2002 .

[22]  T. Tzai,et al.  Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Theodorescu,et al.  Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression , 1998, International journal of cancer.

[25]  C. Bucana,et al.  Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  D. Neal,et al.  Original Articles: Bladder Cancer , 1995 .

[27]  E. Messing.  Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. , 1990, Cancer research.

[28]  A. Harris,et al.  The epidermal growth factor receptor and the prognosis of bladder cancer , 1990, Cancer.

[29]  E. Messing,et al.  Normal and malignant human urothelium: in vitro effects of epidermal growth factor. , 1987, Cancer research.

[30]  M. Bennett,et al.  EPIDERMAL-GROWTH-FACTOR RECEPTORS IN HUMAN BLADDER CANCER: COMPARISON OF INVASIVE AND SUPERFICIAL TUMOURS , 1985, The Lancet.

[31]  A. Harris.  Letter: Vitamin-C-induced hyperoxaluria. , 1976, Lancet.